irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

PURPOSE: irRECIST were designed to capture atypical responses seen with immunotherapy. We hypothesized that, in patients with metastatic clear cell Renal Cell Carcinoma (mccRCC), candidate biomarkers for nivolumab response would show improved association with clinical endpoints capturing atypical re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Pignon, Jean-Christophe, Jegede, Opeyemi, Shukla, Sachet A., Braun, David A., Horak, Christine E., Wind-Rotolo, Megan, Ishii, Yuko, Catalano, Paul J., Grosha, Jonian, Flaifel, Abdallah, Novak, Jesse S., Mahoney, Kathleen M., Freeman, Gordon J., Sharpe, Arlene H., Hodi, F. Stephen, Motzer, Robert J., Choueiri, Toni K., Wu, Catherine J., Atkins, Michael B., McDermott, David F., Signoretti, Sabina
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445699/
https://ncbi.nlm.nih.gov/pubmed/30670497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3206
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge